DTP3 is an experimental therapy developed by a research group at Imperial College London to treat myeloma.

How does DTP3 work?

Myeloma is a type of blood cancer that starts in the bone marrow where blood cells are made. Cancerous myeloma cells can appear simultaneously in the marrow of different bones and spread from one location to another. That is why the disease is often called multiple myeloma.

DTP3 is a small molecule that inhibits two proteins, GADD45b and MKK7, which are part of a signaling pathway called the NF-kB pathway. This pathway is vital to all cells, but is overactive in cancerous cells, promoting the spread and growth of cancer. While this pathway has been known for some time, targeting it in cancer cells without affecting healthy cells has been challenging.

Researchers have discovered that GADD45b and MKK7 are downstream of NF-kB and specific to cancer cells. By blocking or inhibiting these two proteins, NF-kB signaling can be halted. Therefore, because GADD45b and MKK7 are specific to cancer cells, DTP3 should only affect these cells and not healthy ones.

Preclinical studies in mouse tumors have yielded promising results.

DTP3 in clinical trials

A Phase 1/2a pilot trial (EudraCT 2015-003459-23) tested the safety and effectiveness of DTP3 treatment in three patients with relapsed or refractory myeloma, who had received at least two prior lines of therapy but whose cancer was still progressing.

The patients received either 0.5, 1, or 2 mg/kg doses of DTP3 as an intravenous infusion three times a week for four weeks.

The results of the study were published in the British Journal of HaematologyTreatment with DTP3 was able to halt cancer progression in two of the three patients. Researchers hypothesized that the reason why one patient did not respond to the treatment while the other two did was the difference in the amount of GADD45b protein between patients. Based on these findings, they suggested that patients in future studies should be screened for the amount of GADD45b they have prior to treatment.

DTP3 therapy was found to be well-tolerated and had no adverse effects or signs of significant toxicity.

 

Last updated: Jan. 29, 2020

***

Myeloma Research News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health providers with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Emily holds a Ph.D. in Biochemistry from the University of Iowa and is currently a postdoctoral scholar at the University of Wisconsin-Madison. She graduated with a Masters in Chemistry from the Georgia Institute of Technology and holds a Bachelors in Biology and Chemistry from the University of Central Arkansas. Emily is passionate about science communication, and, in her free time, writes and illustrates children’s stories.
Total Posts: 1
Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
×
Emily holds a Ph.D. in Biochemistry from the University of Iowa and is currently a postdoctoral scholar at the University of Wisconsin-Madison. She graduated with a Masters in Chemistry from the Georgia Institute of Technology and holds a Bachelors in Biology and Chemistry from the University of Central Arkansas. Emily is passionate about science communication, and, in her free time, writes and illustrates children’s stories.
Latest Posts
    The User does not have any posts